Loyal is a clinical-stage veterinary medicine company focused on developing innovative drugs aimed at extending the healthy lifespan of dogs. Their primary product in development, LOY-002, targets senior dogs aged 10 and older, with a focus on correcting metabolic dysfunction to enhance longevity. The company is conducting a significant clinical study known as the STAY study, which is a double-blinded, placebo-controlled trial involving 1,000 senior dogs across 70 veterinary clinics in the United States. This study is designed to provide essential safety and efficacy data to support FDA approval for LOY-002, marking a major milestone in veterinary medicine.

In addition to LOY-002, Loyal is also working on other products, such as LOY-001 and LOY-003, which are aimed at large dogs and focus on correcting the overexpression of growth hormones. The company emphasizes preventive care by addressing the underlying causes of age-associated diseases in dogs, thereby delaying their onset and reducing their impact. Loyal's commitment to advancing longevity science for dogs is underscored by their partnerships with veterinary professionals and their ongoing research efforts, which aim to improve the quality of life for aging pets.

United States

Loyal is a clinical-stage veterinary medicine company developing drugs intended to extend the lifespan and healthspan of dogs. In other words, our mission is to help dogs live longer, healthier lives.

We've already achieved significant milestones on our path to gaining FDA approval for the first lifespan extension drug for any species. We have three products in our pipeline and expect to bring the first product to market in 2025.

Our team includes scientists, veterinarians, engineers, operators, and creatives. Join us in our mission to help dogs everywhere.

Loyal

Company Details